<DOC>
	<DOCNO>NCT00437476</DOCNO>
	<brief_summary>The purpose study evaluate combination Lpv/r monotherapy anti-HCV drug match additional toxicity induce association HAART Peg-IFN + ritonavir patient naive HIV HCV . Secondary objective ass Lpv/r monotherapy HCV-treatment associate HIV efficacy v optimize HAART .</brief_summary>
	<brief_title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy ( HAART ) HIV/HCV Coinfected Antiretroviral ( ARV ) Naive Patients Starting Treatment With Anti-HCV Therapy</brief_title>
	<detailed_description>This pilot , randomise , open label , control clinical trial . All eligible patient ( CD4 count &gt; 200 PI resistance ) receive 26 week induction HAART ( LPV/r + select NUCS ) . At end induction period ( Phase I ) , subject negative HIV-RNA least two month , Hb &gt; 11 g/dL CD4 count &gt; 350 cells/mmc randomise ( 1:1 ) , receive LPV/r new tab ( 200/50 mg , 2 cpr BID ) monotherapy ( arm A ) continue HAART ( arm B ) , associate anti-HCV therapy 48 week ( Phase II ) . The number subject recruit 60 subject start induction-phase aim randomize , least 25 subject arm study . The total number subject randomize 50 . The Group A : receive LPV/r + select NRTIs 26 week , follow LPV/r monotherapy anti HCV drug 48 week . Group B : receive LPV/r+ select NRTIs 24 week , follow HAART anti-HCV drug 48 week . At end co-treatment HCV/HIV , subject treat HIV infection accord physician decision.All patient followed-up 24 week end anti-HCV drug evaluation SVR.As anti-HCV drug patient receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At end week 12 combined therapy , patient reach early virological response continue anti-HCV drug .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Hepatitis C Antibodies</mesh_term>
	<criteria>Subject &gt; 18 year old Subject give write informed consent Serologic evidence HIV infection HIV antibody HIVRNA detection Serologic evidence HCV infection HCV antibody HCVRNA detection Subject naive HIV HCV therapy Subject active chronic hepatitis compensate cirrhosis ( ChildPugh class A ) Subject CD4+ count &gt; 200 cell/mm3 &lt; 500 cell/mm3 . Subject genotype available baseline mutation ( IAS ) associate resistance antiretroviral drug use . Subject partner use effective contraceptive method duration study Subject HbsAg positive Subject cirrhosis score ChildPugh B/C , previous hepatic decompensation Subject HIVrelated thrombocytopenia ( Platelets count &lt; 50.000 mmc ) Subject neutrophils count &lt; 1500/mmc Subject Hb value &lt; 9 g/dL screen &lt; 11 g/dL randomization Subject creatinine value &gt; 1.5 mg/dL Subject HAART regimen include ddI and/or AZT Subject pregnant wish become Subject cause liver disease chronic hepatitis C , status liver decompensation condition consistent decompensated liver disease ( bleed esophageal varix , sign current bleeding , significant ascites , hepatic encephalopathy ) Subject alcohol abuser ( &gt; 30 gr/die ) Prior treatment PEGIFN/ribavirin Illicit drug abuse opinion investigator could lead poor compliance term protocol ( maintenance treatment methadone allow ) Active heart disease ( e.g . angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) Subject preexist severe depression , condition severe psychiatric disorder suicidal ideation , suicide attempt , depression acute psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV/HCV</keyword>
	<keyword>HIV HCV coinfected patient</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>